G

Galmed Pharmaceuticals Ltd
D

GLMD

2.72000
USD
0.16
(6.25%)
مغلق
حجم التداول
297
الربح لكل سهم
-1
العائد الربحي
-
P/E
0
حجم السوق
4,507,018
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    -0.350
    (-1.73%)
    19.940 USD
    A
    AMRN
    -0.00130
    (-0.22%)
    0.58930 USD
    C
    CTMX
    -0.03570
    (-4.38%)
    0.78000 USD
    F
    FGEN
    -0.09040
    (-11.70%)
    0.68200 USD
    J
    JAZZ
    -0.640
    (-0.47%)
    136.050 USD
    JNJ
    JNJ
    2.680
    (1.68%)
    162.370 USD
    L
    LIVN
    -0.530
    (-1.10%)
    47.450 USD
    R
    RIGL
    -0.730
    (-3.51%)
    20.090 USD
    S
    SSNC
    -0.520
    (-0.58%)
    88.610 USD
    X
    XENE
    0.410
    (1.04%)
    39.690 USD
    X
    XNCR
    -0.030
    (-0.19%)
    15.740 USD
    المزيد
الأخبار
المقالات

العنوان: Galmed Pharmaceuticals Ltd

القطاع: Healthcare
الصناعة: Biotechnology
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIaclinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.